2021
Breaking the Age Barrier: Physicians’ Perceptions of Candidacy for Allogeneic Hematopoietic Cell Transplantation in Older Adults
Mishra A, Preussler JM, Bhatt VR, Bredeson C, Chhabra S, D'Souza A, Dahi PB, Hacker ED, Gowda L, Hashmi SK, Howard DS, Jakubowski A, Jayani R, Koll T, Lin RJ, Olin RL, Popat UR, Rodriguez C, Rosko A, Sabloff M, Sorror ML, Sung AD, Ustun C, Wood WA, Burns L, Artz A. Breaking the Age Barrier: Physicians’ Perceptions of Candidacy for Allogeneic Hematopoietic Cell Transplantation in Older Adults. Transplantation And Cellular Therapy 2021, 27: 617.e1-617.e7. PMID: 33836312, PMCID: PMC8254775, DOI: 10.1016/j.jtct.2021.03.028.Peer-Reviewed Original ResearchConceptsAllogeneic hematopoietic cell transplantationHematopoietic cell transplantationGeriatric assessmentOlder adultsPatient ageCell transplantationHCT physiciansHigh-volume teaching hospitalStandardized geriatric assessmentTransplantation-related morbidityAge 75 yearsSignificant unmet needOnline cross-sectional surveyHealth assessment toolClinical support staffCross-sectional surveyMyeloablative regimenRegimen intensityNonmyeloablative conditioningRisk stratificationTransplant physiciansTeaching hospitalAge 41Most physiciansUnmet need
2020
Physician and patient acceptance of policies to reduce kidney discard
Mehrotra S, Schantz K, Friedewald JJ, Ladner DP, Becker Y, Formica R, Barah M, Gu J, Gordon EJ. Physician and patient acceptance of policies to reduce kidney discard. Clinical Transplantation 2020, 34: e14054. PMID: 32738167, PMCID: PMC7929781, DOI: 10.1111/ctr.14054.Peer-Reviewed Original ResearchConceptsDeceased donor kidneysMajority of physiciansDonor kidneysKidney allocation policyShortage of kidneysRisk of discardAggressive centersGraft failureSurvival benefitSuitable patientsTransplant physiciansPatient acceptancePatientsKidneyPhysiciansPatient organizationsProfessional societiesKDPITransplantationMajorityMonthsTransplant Physicians’ Attitudes on Candidacy for Allogeneic Hematopoietic Cell Transplantation (HCT) in Older Patients: The Need for a Standardized Geriatric Assessment (GA) Tool
Mishra A, Preussler J, Al-Mansour Z, Bachanova V, Bhatt V, Bredeson C, Chhabra S, D'Souza A, Dahi P, DeFilipp Z, Gowda L, Hacker E, Hashmi S, Howard D, Jakubowski A, Jayani R, Johnston L, Koll T, Lin R, McCurdy S, Michaelis L, Muffly L, Nathwani N, Olin R, Popat U, Rodriguez C, Rosko A, Runaas L, Sabloff M, Shore T, Shune L, Sorror M, Sung A, Ustun C, Wood W, Burns L, Artz A. Transplant Physicians’ Attitudes on Candidacy for Allogeneic Hematopoietic Cell Transplantation (HCT) in Older Patients: The Need for a Standardized Geriatric Assessment (GA) Tool. Transplantation And Cellular Therapy 2020, 26: s45-s46. DOI: 10.1016/j.bbmt.2019.12.115.Peer-Reviewed Original ResearchHematopoietic cell transplantationKarnofsky performance scoreTransplant physiciansUpper age limitAllogeneic hematopoietic cell transplantationGeriatric assessment toolsNon-myeloablative conditioningMarrow Transplant ResearchOnline cross-sectional surveyHealth assessment toolMajority of centersClinical support staffCross-sectional surveyAssessment toolAdult physiciansMyeloablative regimenOlder ptsRegimen intensityConditioning regimensOlder patientsSupportive careInternational BloodRisk stratificationCell transplantationCurative potential
2019
HLA, Non-HLA Antibodies, and Eplet Mismatches in Pediatric Liver Transplantation: Observations From a Small, Single-Center Cohort.
Ekong UD, Antala S, Bow L, Sese D, Morotti R, Rodriguez-Davalos M, Gan G, Deng Y, Emre SH. HLA, Non-HLA Antibodies, and Eplet Mismatches in Pediatric Liver Transplantation: Observations From a Small, Single-Center Cohort. Experimental And Clinical Transplantation 2019, 17: 6-17. PMID: 30777518, PMCID: PMC11165937, DOI: 10.6002/ect.mesot2018.l30.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAge FactorsChildChild, PreschoolConnecticutFemaleGraft RejectionGraft SurvivalHistocompatibilityHistocompatibility TestingHLA AntigensHumansImmunosuppressive AgentsInfantIsoantibodiesLiver TransplantationMaleRetrospective StudiesRisk FactorsTime FactorsTreatment OutcomeYoung AdultConceptsDonor-specific antibodiesEpitope mismatchesMismatch loadAcute rejectionClass II donor-specific antibodiesDQ lociDQ Donor-Specific AntibodiesNon-HLA antibodiesAntibody-mediated rejectionPediatric liver transplantationSingle-center cohortHLAMatchmaker softwareImmunosuppression strategiesLiver transplantLiver transplantationAllograft fibrosisEplet mismatchesLiver biopsyPediatric patientsFibrosis scoreHLA-DRRetrospective reviewTransplant physiciansHLA-DQHLA-DQB1
2017
Transfusion Support of the Patient with Sickle Cell Disease Undergoing Transplantation
Hendrickson J, Fasano R. Transfusion Support of the Patient with Sickle Cell Disease Undergoing Transplantation. 2017, 111-136. DOI: 10.1007/978-3-319-62328-3_5.Peer-Reviewed Original ResearchHematopoietic stem cell transplantationSickle cell diseaseRed blood cellsTransfusion supportTransplant physiciansConditioning regimen intensityOptimal transplant outcomesPeri-transplant periodHigher red blood cellStem cell transplantationTransfusion medicine physiciansRegimen intensityUndergoing transplantationPosttransplant periodTransplant outcomesHSCT populationCurative therapyPlatelet transfusionsSCD patientsTransfusion managementCell transplantationTransfusion therapyDonor selectionIron overloadCell disease
2012
Toxic erythema of chemotherapy following i.v. BU plus fludarabine for allogeneic PBSC transplant
Parker TL, Cooper DL, Seropian SE, Bolognia JL. Toxic erythema of chemotherapy following i.v. BU plus fludarabine for allogeneic PBSC transplant. Bone Marrow Transplantation 2012, 48: 646-650. PMID: 23165491, DOI: 10.1038/bmt.2012.218.Peer-Reviewed Original ResearchConceptsAllogeneic PBSC transplantCutaneous toxicityConditioning regimenPBSC transplantsToxic erythemaLow treatment-related mortalityDoses of BUEffective conditioning regimenPalms/solesTreatment-related mortalityEvaluable patientsMost patientsMedian onsetStandard dosesTransplant physiciansClinical presentationScrotal involvementSpecific therapyAllergic reactionsInappropriate treatmentRetrospective analysisHigh incidencePatientsMyeloid neoplasiaBU/
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply